Skip to content

Treating Comorbid Pain and Depression in HIV+ Individuals

Treating Comorbid Pain and Depression in HIV+ Individuals

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02766751
Acronym
HIVPass
Enrollment
187
Registered
2016-05-10
Start date
2016-11-15
Completion date
2021-05-31
Last updated
2021-06-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression, HIV, Pain

Brief summary

This study is designed to look at two different programs that may help people who are HIV+ and have pain and depression. The investigators are trying to understand how to help people learn to live better lives even with these chronic illnesses.

Detailed description

The primary aim of this RCT is to evaluate the HIVPass intervention. HIV+ participants (n=236) with chronic pain and depression will be recruited at primary care HIV Clinics through posted advertisements in the waiting rooms of the PCP offices and by physician referral. After an initial phone study screen, research staff will meet with interested individuals in their PCP offices for informed consent, baseline interview and randomization into one of two study groups (Health Education or HIVPass Counseling). Seven intervention sessions (HE or HIVPASS) will occur during the first 3 months of study participation. For all participants, the first session is a collaborative in-person joint session with the participant, his/her PCP and the study BHS. Session 2 is conducted immediately after this collaborative session, and is also in-person. Sessions 3-7 are conducted by phone. Follow-up assessment interviews will be at months 1, 2, 3 (post-intervention), 4, 6, 9 and 12.

Interventions

BEHAVIORALHIVPASS

The 7-session HIVPASS intervention is provided to individuals randomized to the HIVPASS study arm.

BEHAVIORALHealth Education

The 7-sessions of Health Education is provided to individuals randomized to the Health Education study arm.

Sponsors

Butler Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Chronic Pain (pain duration for at least six months with a mean score of greater than 3.5 on the BPI Pain Interference Scale) * Pain severity \> or equal to 4 on a Numeric Rating Scale indicating average pain in the last week * At least one trial of PCP-recommended medication (i.e. acetaminophen, NSAIDS, muscle relaxants) judged through interviews with patients and PCPs * Quick Inventory of Depression Symptoms (QIDS) score of ≥ 9 (depression severity) * Stable dose of an antidepressant, if using, for the previous 1 months * Age \> or equal to 18 * HIV+ * Planning to live in the area for the next 6 months * Access to a telephone that is typically working.

Exclusion criteria

* In psychotherapy or a multidisciplinary pain management program * Planned surgery in the next 6 months * Pain thought due to cancer * Current mania * Past year chronic psychotic condition * Excessive substance use (Use of cocaine, heroin, or non-prescribe opioids 15 days per month or more; binge alcohol use 4 days per month or more) * Suicidality requiring immediate attention * Pregnancy or planned pregnancy in the next 6 months

Design outcomes

Primary

MeasureTime frameDescription
pain interference3 monthsBrief pain inventory, interference scale

Secondary

MeasureTime frameDescription
activity level3 months; 12 monthsAssessed with actigraphy
anxiety3 months; 12 monthsState-Trait Anxiety Inventory
viral load3 months, 12 months
depression3 months; 12 monthsQuick Inventory of depression symptoms
perception of global improvement3 months, 12 monthsPatient Global Impression of Change Scale
health related quality of life3 months, 12 onthsShort Form 36 Health Survey
pain interference12 monthsbrief pain inventory, interference scale
ART adherence3 months, 12 monthsAIDS Clinical Trial Group questionnaire

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 28, 2026